$MRNS: Marinus Pharmaceuticals announces top-line
Post# of 22755
Posted On: 06/28/2016 1:52:44 PM
$MRNS: Marinus Pharmaceuticals announces top-line data from a Phase 2 study to evaluate ganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome; primary endpoint was not met - 7:31 AM ET 6/28/16 | Briefing.com - The co announced top-line data from a Phase 2 exploratory, investigator-sponsored study to evaluate the safety, tolerability and efficacy of ganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome. The investigator selected Clinical Global Impression of Improvement, which is a broad scale to assess the overall improvement across the entire Fragile X Syndrome, as the primary endpoint of the study.
Was up big this morning and moved lower and now starting to go higher again.
Was up big this morning and moved lower and now starting to go higher again.
(0)
(0)Scroll down for more posts ▼